The Motley Fool
26 Jul 2026, 18:45 UTC · 1h ago
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
26 Jul 2026, 18:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Teva is developing duvakitug for ulcerative colitis and Crohn's disease, with projected peak annual sales between $2 billion and $5 billion. — A potential blockbuster drug of this magnitude would significantly increase the company's valuation and revenue ceiling.
+0.80Teva expects a 30% increase in operating profit and adjusted EBITDA starting next year, driven by the launch of biosimilars. — Significant growth in core profitability metrics usually leads to a positive rerating of the stock price.
+0.60Teva's branded drugs, including Austedo, Ajovy, and Uzedy, are currently achieving mid-double-digit annual sales growth. — Confirms the successful pivot from generics to higher-margin branded pharmaceuticals, supporting long-term stability.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Management expects a decline in earnings per share (EPS) from $2.65 in 2025 to between $1.91 and $2.11 in 2026 due to the acquisition of Emalex Biosciences. — A projected drop in EPS typically creates short-term downward pressure on the stock price despite the strategic rationale.
-0.30Which stocks this story touches
The company has shown strong recovery through a shift to branded drugs and has a potential blockbuster drug candidate in its pipeline.
Sanofi is co-developing a promising drug candidate for ulcerative colitis and Crohn's disease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
10h ago
